Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern

Spyre Therapeutics, Inc.

Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.
Company received SEC waiver to file abbreviated financials for Spyre acquisition; net liabilities assumed of $17.0M.
Substantial doubt about going concern if stockholders do not timely approve Series A Preferred Stock conversion.
As of June 22, 2023, Spyre had cash $3.0M and accrued liabilities $20.0M; total acquisition cost was $113.2M.
Company reduced workforce by 83% in April 2023 to ~10 employees; exploring strategic alternatives.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cameron Turtle

principal executive officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-10-06
Filed: October 10, 2023, 7:59 PM ET

On October 6, 2023, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Dr. Cameron Turtle, the Company’s Chief Operating Officer, as the principal executive officer of the Company, effective as of the same day.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cameron Turtle was appointed as principal executive officer at Spyre Therapeutics, Inc..

Action: appointed
Role: principal executive officer

Exact text from the filing

On October 6, 2023, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Dr. Cameron Turtle, the Company’s Chief Operating Officer, as the principal executive officer of the Company, effective as of the same day.

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-252523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.